The text starts here.

News Release

FOR IMMEDIATE RELEASE
April 14, 1997

Eisai Announces Completion of US Process Research Facility

Tokyo (April 14, 1997) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced the completion of its process research facility, Eisai Merrimack Valley Laboratories, Inc. (EMV) in Andover, Massachusetts on April 10.


The facility will be engaged in process research for chemical compounds resulting from Eisai's drug discovery research operations, finding best routes for compound synthesis, activities into synthesis methods for large scale production, and the supply of drug substances for clinical trial use.


Initially the facility will focus on supplying the clinical trial substance for Eisai's compound (Eisai code number: E5531) currently in Phase II clinical trials for septic shock.


EMV neighbors Eisai's principal US research facility Eisai Research Institute of Boston (ERI). The EMV facility is located on a land area of 27 acres and the structure encompasses a total floor area of 41,100 square feet which houses analytical and process chemistry development laboratories, a state-of-the-art, three story micro-plant, and administrative offices.


An portion of the EMV site including a pond and wetlands area will remain undeveloped to protect natural wildlife. In addition, the facility incorporates advanced pollution control technology to limit emissions into the environment.


(EMV OUTLINE)


Name: Eisai Merrimack Valley Laboratories, Inc.
Establishment: November 1994
Location: Andover, Massachusetts
Total Land Area: 26.8 acres (108,460 square meters)
Total Facility Area: 41,100 square feet (3,822 square meters)
Employees: 35
Construction cost: approximately $30 million

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported sales of $2.6 billion in 1995 with approximately 14 percent of sales spent for research and development.